Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Solid tumours
Dose: Intravenous – 4-10 mg (0.06-0.15 mg/kg)
Frequency: given at 1-6 weekly intervals
Note: Intervals depend on whether other drugs are given in combination and on bone marrow recovery.
Indication: Solid tumours
Dose: Intravenous – 10 mg/m2 of body surface area
Note: Course being repeated at intervals for as long as required. Often required for a satisfactory response when used alone or in combination.

Child Dose

Clinical InformationAdministration Information
Age: Pediatric
Dose: Safety and efficacy not established
Note: Safety and efficacy not established

Renal Dose

Clinical InformationAdministration Information
Condition: Serum creatinine greater than 1.7 mg/dL
Dose: Not specified
Note: Avoid use
Condition: Creatinine Clearance less than 10 mL/min
Dose: Not specified
Note: Decrease dose by 25%
Administration
  • For IV use only
  • Must be given slowly
Side Effect

Drug Interaction

Drug NameRisk Factors
Doxorubicin
Increased incidence of cardiotoxicity
Fluorouracil
Potentially Fatal: Increased risk of intravascular haemolysis and renal failure

Disease Interaction

Disease NameRisk Factors
Low platelet count (<100,000/mm3)
Bleeding risk
Coagulation disorders
Severe bleeding risk

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Powder for injection: Store between 15-30°C. Protect from light.

Reconstituted solution: Stable for 1 wk when stored between 15-25°C and 2 wk when stored between 2-8°C.

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.